We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Protective Effect of EPA on Cardiovascular Events

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00231738
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : November 20, 2015
Mochida Pharmaceutical Company, Ltd.
Information provided by:
Kobe University

Brief Summary:
The purpose of this study was to test the hypothesis that the long-term use of highly (>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.

Condition or disease Intervention/treatment Phase
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease Drug: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM) Phase 4

Detailed Description:

Epidemiological studies from many countries including Finland, Italy, Japan, and The Netherlands have suggested that an increased intake of dietary fish or fish oil rich in the long-chain polyunsaturated n-3 fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is inversely related to the risk of atherothrombotic diseases, in particular coronary artery disease (CAD).

Results of many prospective observational cohort studies have found that diets rich in marine PUFAs may be protective against major cardiovascular events, including mortality from CAD, total cardiovascular death, all-cause mortality, and nonfatal myocardial infarction. To date, only a few studies have examined the effects of purified n-3 PUFA preparations in human subjects for short observation periods. The principle aim of the current study is to test the hypothesis that the long-term use of highly purified EPA(eicosapentaenoic acid: 1800mg/day), in addition to HMG-CoA reductase inhibitor, is effective in preventing cardiovascular events in Japanese patients with hypercholesterolemia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 18000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)
Study Start Date : November 1996
Study Completion Date : November 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina

Primary Outcome Measures :
  1. Major coronary events (sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina pectoris including hospitalization for ischemic episodes,events of angioplasty/ stenting or coronary artery bypass grafting)

Secondary Outcome Measures :
  1. All-cause mortality
  2. Stroke
  3. Peripheral artery disease; and
  4. Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eligible participants had a total cholesterol level of ≧250mg/dL(6.5m mol/L) at baseline.
  • Hyperlipidemic patients with serum total cholesterol of 250mg/dL or more. (Measurement of serum total cholesterol)
  • Serum total cholesterol should be measured twice at interval of 2-4weeks. A single measurement is acceptable if the cholesterol is measured by blood collection at fasting under strict compliance with dietary advice after withdrawal of the antihyperlipemic drug.
  • (Wash Out) The wash out period of 4weeks (8 weeks for probucol) is necessary in patients under treatment with antihyperlipemic drug. However, if treatment with the antihyperlipemic drug was started within 6 months of the initiation of the study, the patient can participate in the study without the washout period.

Exclusion Criteria:

  • Acute myocardial infarction occurring within last 6 months
  • Unstable angina pectoris
  • A history or complication of serious heart disease(severe arrhythmia, heart failure, cardiac myopathy, valvular disease, congenital disease, etc.)
  • Receiving cardiovascular reconstruction within last 6 months
  • Cerebrovascular disorders occurring within last 6 months
  • Complication of serious hepatic disease or renal disease
  • Malignant tumor
  • Uncontrollable diabetes
  • Hyperlipidemia arising from the following disease: Nephrotic syndrome, hypothyroidism, Cushing's syndrome, secondary hyperlipidemia due to other disease
  • Hyperlipidemia due to some drugs such as steroid hormone
  • Hemorrhage(hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.)
  • Hemorrhagic diathesis
  • Hypersensitivity to the study drug formulation
  • Patients intending to undergo surgery
  • Patients judged to be inappropriate by the physician in charge

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00231738

Layout table for location information
Kobe University Graduate School of Medicine Cardiovascular and Respiratory Medicine Division, Department of Internal Medicine
Kobe, Hyogo-prefecture, Japan, 650-0017
Sponsors and Collaborators
Kobe University
Mochida Pharmaceutical Company, Ltd.
Layout table for investigator information
Principal Investigator: Mitsuhiro Yokoyama, MD, PhD.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00231738    
Other Study ID Numbers: MYokoyama - 001
First Posted: October 4, 2005    Key Record Dates
Last Update Posted: November 20, 2015
Last Verified: October 2005
Keywords provided by Kobe University:
Eicosapentaenoic acid
Coronary artery disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Peripheral Arterial Disease
Angina Pectoris
Death, Sudden, Cardiac
Angina, Unstable
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Peripheral Vascular Diseases
Chest Pain
Neurologic Manifestations
Heart Arrest
Death, Sudden
Eicosapentaenoic acid ethyl ester
Platelet Aggregation Inhibitors
Lipid Regulating Agents